CAR-T Therapies

CTAF

ICER will develop a report on chimeric antigen receptor t-cell (CAR-T) therapies for treatment of B-cell malignancies. ICER’s report is expected to consider the comparative clinical effectiveness and value of tisagenlecleucel (KymriahTM [CTL-019], Novartis) and axicabtagene ciloleucel (KTE-019, Kite Pharma). Tisagenlecleucel was approved by the FDA is August of 2017; an approval decision for axicabtagene ciloleucel is expected in December of 2017, respectively.  If approved, tisagenlecleucel-t is expected to be used in the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia in pediatric and young adult patients. Novartis is also expected to file later this year for a second indication for diffuse large B-cell lymphoma in adults. Axicabtagene ciloleucel is under review for the treatment of relapsed or refractory aggressive non-Hodgkin’s lymphoma in adult patients who are not eligible for autologous stem cell transplant.

Date of Review: March 2018

Associated Meetings

March 2, 2018 10am-4pm PT

California, TBD

The California Technology Assessment Forum will convene to discuss evidence on CAR-T therapies.


Key Dates

Associated Materials

03/02/2017

Public meeting of CTAF.

Meeting Agenda

07/19/2017

07/19/2017 – 08/04/2017

08/09/2017

08/09/2017 – 08/29/2017

09/07/2017

10/16/2017

10/16/2017

12/19/2017
Draft Evidence Report

12/19/2017 – 01/24/2018
Public Comments

02/15/2018
Evidence Report

03/16/2018
Final Evidence Report and Meeting Summary